The Impact of Stopping Weight-Loss Drug: Eli Lilly Stock Tumbles

Eli Lilly's stock dropped over 4% after a study revealed that patients who stopped taking the weight-loss drug Zepbound slowly regained weight over a year. The study, published in the Journal of the American Medical Association, highlights the long-term impact of discontinuing treatment with weight-loss drugs. Patients who switched to a placebo regained weight, but not as much as they had originally lost. Eli Lilly's new weight-loss drug, Zepbound, helped patients lose an average of 20.9% of their weight over eight months, while those who continued taking the drug lost an additional 5.5%. The study emphasizes the need for ongoing treatment for obesity, which is often a chronic disease. Eli Lilly's stock fell, as did shares of rival Novo Nordisk.